Form 4: Exact Sciences Director Shacey Petrovic Receives Equity Grant as Part of Compensation

Exact Sciences Corporation Director Shacey Petrovic acquired 5,398 shares of common stock on June 12, 2025, as part of the company's non-employee director compensation policy, increasing her direct beneficial ownership to 21,804 shares.

Summary

• Shacey Petrovic, a Director of Exact Sciences Corp. (EXAS), acquired 5,398 shares of common stock.
• The transaction occurred on June 12, 2025.
• These shares were issued at a price of $0, indicating they are part of the Company's non-employee director compensation policy.
• Following this acquisition, Ms. Petrovic directly beneficially owns 21,804 shares of common stock.
• Additionally, she indirectly beneficially owns 7,095 shares through a grantor retained annuity trust.
• The filing also includes a Power of Attorney, dated May 14, 2025, authorizing specific individuals (Mark Busch, James Herriott, Henry Weiner, Ashley Hein, and Aaron Dixon) to act on behalf of Shacey Petrovic for SEC filings and related matters.

Sentiment

Score: 6

Explanation: The document reports a routine insider transaction (stock grant) and a standard Power of Attorney. It's mildly positive as it shows director equity ownership, but doesn't contain significant news to warrant a high score.

Positives

• Acquisition of 5,398 shares by a director, indicating alignment of interests with shareholders.
• The shares were granted as part of a compensation policy, which is a standard practice for non-employee directors.

Risks

• The Power of Attorney explicitly states that it does not relieve the undersigned (Shacey Petrovic) from responsibility for compliance with her obligations under Section 13 or Section 16 of the Exchange Act, including reporting requirements and potential disgorgement of profits under Section 16(b).

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions, common across all publicly traded companies. The grant of restricted stock to a non-employee director as part of compensation is a standard practice in the industry to align director interests with shareholder value.

Comparison to Industry Standards

• This document reports a standard equity grant to a non-employee director, which is a common compensation practice across publicly traded companies, including those in the healthcare and diagnostics sector like Exact Sciences.
• There are no specific comparable companies, projects, or results detailed in this filing to allow for a direct performance comparison.

Corporate Governance

Related Party Transactions

• The acquisition of 5,398 shares of common stock by Director Shacey Petrovic at a $0 price is a related party transaction, as it constitutes compensation under the company's non-employee director compensation policy.

Stakeholder Impact

• Shareholders: The acquisition of shares by a director aligns their interests with shareholders, potentially fostering long-term value creation.
• Employees/Management: The Power of Attorney streamlines compliance processes for insider reporting, benefiting the company's administrative efficiency.

Next Steps

• The document does not explicitly mention future actions, events, or milestones for the company, beyond the ongoing requirement for the reporting person to file SEC forms.

Key Dates

Recommendation

Keywords

Exact Sciences, EXAS, Shacey Petrovic, Director Compensation, Stock Grant, SEC Form 4, Insider Trading, Beneficial Ownership, Equity Compensation, Power of Attorney